Emma K. Jennings

Emma K. Jennings

Auto-generated profile, based on publicly available information

Emma K. Jennings

Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Immunity
Verified
Journal Article
Open access
TEThomas A.E. Elliot
Thomas A.E. Elliot
EJEmma K. Jennings
Emma K. Jennings
DLDavid A.J. Lecky
David A.J. Lecky
NTNatasha Thawait
Natasha Thawait
AFAdriana Flores-Langarica
Adriana Flores-Langarica
DBDavid Bending
David Bending
How T cell receptor (TCR) signal strength modulates T cell function and to what extent this is modified by immune checkpoint blockade (ICB) are key questions in immunology. Using Nr4a3-Tocky mice, we characterized early quantitative and qualitative changes that occur in CD4+ T cells in relation to TCR signaling strength. We captured how dose- and time-dependent programming of distinct co-inhibitory receptors rapidly recalibrates T cell activation thresholds and visualized the immediate effects of ICB on T cell re-activation. Our findings reveal that anti-PD1 immunotherapy leads to an increased TCR signal strength. We defined a strong TCR signal metric of five genes upregulated by anti-PD1 in T cells (TCR.strong), which was superior to a canonical T cell activation gene signature in stratifying melanoma patient outcomes to anti-PD1 therapy. Our study therefore reveals how analysis of TCR signal strength—and its manipulation—can provide powerful metrics for monitoring outcomes to immunotherapy.

1 March 2021 in STAR Protocols
Verified
Journal Article
Open access
EJEmma K. Jennings
Emma K. Jennings
DLDavid A.J. Lecky
David A.J. Lecky
MOMasahiro Ono
Masahiro Ono
DBDavid Bending
David Bending
This protocol uses Nr4a1-GFP Nr4a3-Tocky mice to study T cell receptor (TCR) signaling using flow cytometry. It identifies the optimal mouse transgenic status and fluorochromes compatible with the dual reporter. This protocol has applications in TCR signaling, and we outline how to obtain high-quality datasets. It is not compatible with cellular fixation, and cells should be analyzed immediately after staining.

23 September 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
EJEmma Jennings
Emma Jennings
TEThomas A.E. Elliot
Thomas A.E. Elliot
NTNatasha Thawait
Natasha Thawait
SKShivani Kanabar
Shivani Kanabar
JYJuan Carlos Yam-Puc
Juan Carlos Yam-Puc
DBDavid Bending
David Bending
Summary: Nr4a receptors are activated by T cell receptor (TCR) and B cell receptor (BCR) signalling and play key roles in T cell differentiation and promoting T cell exhaustion. How TCR signalling pathways regulate Nr4a receptors and their sensitivities to different physiological types of TCR signalling (e.g. tonic versus activating) remains unknown. Here we utilise Nr4a1/Nur77-GFP and Nr4a3 -Tocky mice to elucidate the signalling pathways that govern Nr4a receptor expression in CD4 + and CD8 + T cells. Our findings reveal that Nr4a1-3 are Src family kinase-dependent. Moreover, Nr4a2 and Nr4a3 are abolished by calcineurin inhibitors and bind NFAT1, highlighting a necessary and sufficient role for NFAT in the control of Nr4a2 and Nr4a3 , but redundancy for NFAT for Nr4a1 . During T cell development, Nr4a1 is activated by tonic signalling during TCR-beta selection in the thymus, whilst Nr4a3 requires cognate peptide:MHC interactions for expression. Thus, due to differential sensitivity of Nr4a1 and Nr4a3 to TCR signalling pathways, T cells undergoing tonic versus activating TCR signalling events can be distinguished in vivo.

13 June 2019 in British Journal of Nursing
Verified
Journal Article
Closed access
CRCherie Rushton
Cherie Rushton
EBElizabeth Bacon
Elizabeth Bacon
EJEmma Jennings
Emma Jennings
PMPaula Marchetti
Paula Marchetti
AAArun Alfred
Arun Alfred
Graft versus host disease (GvHD) is a serious and common complication of allogenic haematopoietic stem cell transplant. Corticosteroids are considered the standard care for initial treatment of GvHD but a significant proportion of patients will need long-term steroid treatment for control of GvHD. Extracorporeal photopheresis (ECP) is a cell-based immunomodulatory therapy that is an accepted second line treatment in patients with steroid refractory, dependent or intolerant GvHD and has shown efficacy in allowing steroid dose reduction and discontinuation in this cohort of patients. Adrenal cortical insufficiency is defined by the inability of the adrenal cortex to produce sufficient amounts of glucocorticoids and/or mineralocorticoids leading to a severe and potentially life-threatening condition. The most common cause of drug-induced adrenal insufficiency is the suppression of the hypothalamic–pituitary–adrenal axis by exogenous glucocorticoid doses ≥5 mg prednisolone equivalent for more than 4 weeks. The aim of the study was to ascertain the number of patients with GvHD receiving ECP that are affected by adrenocortical insufficiency.

9 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLozan Sheriff
Lozan Sheriff
ACAlastair Copland
Alastair Copland
DLDavid A.J. Lecky
David A.J. Lecky
RDReygn Done
Reygn Done
LGLorna S George
Lorna S George
DBDavid Bending
David Bending
Summary: Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early CD4 + T cell activation remains unclear. Here, we show that the PD-1 and Lag3 pathways exhibit layered control of the early CD4 + T cell activation process, with the effects of Lag3 more pronounced in the presence of PD-1 pathway co-blockade (CB). RNA-sequencing revealed that CB drove an early NFAT-dependent transcriptional profile, including promotion of ICOS hi T follicular helper (Tfh) cell differentiation. NFAT pathway inhibition abolished CB-induced upregulation of NFAT-dependent co-receptors ICOS and OX40, whilst unaffecting the NFAT-independent gene Nr4a1 . Mechanistically, Lag3 and PD-1 pathways functioned additively to regulate the duration of T cell receptor (TCR) signals during CD4 + T cell re-activation. Our data therefore reveal that PD-1 and Lag3 pathways converge to additively regulate TCR signal duration and NFAT-dependent transcriptional activity during early CD4 + T cell re-activation. Highlights: PD-1 and Lag3 pathways exhibit layered control of early CD4 + T cell activation Their co-blockade enhances NFAT-dependent TCR transcriptional programmes Inhibition of NFAT signalling reverses the functional effects of PD-1 and Lag3 co-blockade Mechanistically, PD-1 and Lag3 function to additively regulate TCR signal duration during re-activation of CD4 + T cells

2 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
TEThomas A.E. Elliot
Thomas A.E. Elliot
EJEmma K. Jennings
Emma K. Jennings
DLDavid A.J. Lecky
David A.J. Lecky
NTNatasha Thawait
Natasha Thawait
AFAdriana Flores-Langarica
Adriana Flores-Langarica
DBDavid Bending
David Bending
Summary: How T cell receptor (TCR) signal strength modulates T cell function and to what extent this is modified by immune checkpoint blockade (ICB) are key questions in immunology. Using Nr4a3-Tocky mice as a digital read-out of NFAT pathway activity, we identify the rapid quantitative and qualitative changes that occur in CD4 + T cells in response to a range of TCR signalling strengths. We demonstrate that the time and dose dependent programming of distinct co-inhibitory receptors rapidly re-calibrates T cell activation thresholds. By developing a new in vivo model, we analyse the immediate effects of ICB on T cell re-activation. Our findings reveal that anti-PD1 but not anti-Lag3 immunotherapy leads to an increased TCR signal strength. We define a strong TCR signal metric of five genes specifically upregulated by anti-PD1 in T cells (TCR.strong), which can stratify clinical outcomes during anti-PD1 monotherapy in melanoma patients. Our study therefore reveals how analysis of TCR signal strength – and its manipulation – can provide powerful metrics for monitoring outcomes to immunotherapy. Key Points: TCR signal strength-dependent programming of CD4 + T cells revealed over time in vivo Inhibitory receptor expression is dynamic, TCR signal strength dependent, and rapidly re-calibrates T cell activation thresholds PD1 but not Lag3 blockade leads to a unique and increased TCR signal strength signature (coined TCR.strong) TCR.strong metric stratifies melanoma patient survival in response to Nivolumab (anti-PD1) therapy